Skip to main content
Log in

Newly discovered anti-inflammatory properties of the benzamides and nicotinamides

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Our laboratory has concentrated on the possible regulation the benzamides and nicotinamides may have on the processes of DNA repair and apoptosis. Recent reports [14-16] have suggested that both apoptosis and inflammation are regulated by the transcription factor NF-kB. We have initiated studies regarding the hypothesis that the benzamides and nicotinamides could inhibit the production of tumor necrosis factor alpha (TNFalpha) and the inflammatory response as well as induce apoptosis via inhibition of NF-kB. Our data have shown that nicotinamide and two N-substituted benzamides, metoclopramide (MCA) and 3-chloroprocainamide (3-CPA), gave dose dependent inhibition of lipopolysacharide induced TNFalpha in the mouse within the dose range of 10-500 mg/kg. Moreover, lung edema was prevented in the rat by 3 ï 50 mg/kg doses of 3-CPA or MCA, and 100-200 μM doses of MCA could also inhibit NF-kB in Hela cells. Taken together these data strongly support the notion that benzamides and nicotinamides have potent anti-inflammatory and antitumor properties, because their primary mechanism of action is regulated by inhibition at the gene transcription level of NF-kB, which in turn inhibits TNFalpha and induces apoptosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stanley, Rotrosen (eds). The Benzamides: Pharmacology, Neurobiology and Clinical Aspects. Raven Press, New York, 1982

    Google Scholar 

  2. Horsman MR: Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncol 34: 571–587, 1995

    PubMed  Google Scholar 

  3. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 25: 451–494, 1983

    PubMed  Google Scholar 

  4. Pero RW, Olsson A, Amiri A, Chaplin D: Multiple modes of action of the benzamides and nicotinamides as sensitizers of radio-and chernotherapies. Opportunities for drug design. Cancer Prev Det 22(3): 225–236, 1998

    Google Scholar 

  5. King FD, Sanger GJ: 5–HT3 receptor antagonists. Drugs Future 14: 875–889, 1989

    Google Scholar 

  6. Pero RW, Olsson A, Sheng Y, Hua J, Mç1ler C, Kjellén E, Killander D, Marmor M: Progress in identifying clinical relevance of inhibition, stimulation and measurement of poly ADP-ribosylation. Biochimic 77: 385–393, 1995

    Google Scholar 

  7. Olsson A, Pero RW, Olofsson T: Specific binding and active transport of nicotinamide in human leukernic K562 cells. Biochem Pharmacol 45: 1191–1200, 1993

    PubMed  Google Scholar 

  8. Olsson A, Sheng Y, Kjellén E, Pero RW: In vivo measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 16(5): 1029–1035, 1995

    PubMed  Google Scholar 

  9. Olsson A, Sheng Y, Pero RW, Chaplin D, Horsman M: DNA damage and repair in tumour and nontumour tissues of mice induced by nicotinamide. Brit J Cancer 74: 368–373, 1996

    PubMed  Google Scholar 

  10. Pero RW, Olsson A, Simanaitis M, Amiri A, Andersen I: Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, Sensamiode and Neu-Sensamide. Pharmacol Toxicol 80: 231–239, 1997

    PubMed  Google Scholar 

  11. Olsson AK, Hua J, Sheng Y, Pero RW: Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. Acta Oncol 36(3): 321–328, 1997

    Google Scholar 

  12. Jacobson MK, Cervantes-Lauran D, Strohm MS, Coyle DL, Bummer PM, Jacobson EL: NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Biochimie 77: 341–344, 1995

    PubMed  Google Scholar 

  13. Lee HC, Graef R, Walseth TF: Cyclic ADP-ribose and its metabolic enzymes. Biochimie 77: 345–355, 1995

    PubMed  Google Scholar 

  14. Beg AA, Baltimore D: An essential role for NF-kB in preventing TNFalpha induced cell death. Science 274: 782–784, 1996

    PubMed  Google Scholar 

  15. Wang C-Y, Mayo MW, Baldwin AS: TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kB. Science 274: 784–787, 1996

    PubMed  Google Scholar 

  16. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNFalpha-induced apotosis by NF-kB. Science 274: 787–789, 1996

    PubMed  Google Scholar 

  17. Barnes PJ, Adcock IM: NF-kB: A pivotal role in asthma and a new target for therapy. TIPS 18: 46–50, 1997

    PubMed  Google Scholar 

  18. Robert-Piessard S, LeBaut G, Courant J, et al.: Non-acidic antiinflammatory compounds: Activity of N-(4–6–dimethyl-2–pyridinyl) benzamides and derivatives. Eur J Med Chem 25: 9–19, 1990

    Google Scholar 

  19. Moffett RB, Robert A, Skaletzky LL: Antiulcer agents. p-aminobenzamido aromatic compounds. J Med Chem 14(10): 963–968, 1971

    PubMed  Google Scholar 

  20. Piriou R, Petit JY, Welin I: Benzamide potentiation of behavioral apomorphine-induced effects: Mechanism involved. Experientia 41: 1409–1410, 1985

    PubMed  Google Scholar 

  21. Bouhayat S, Piessard S, LeBaut G, Sparfel L, Petit J-Y, Piriou F, Welin I: Synthesis and central dopaminergic effects of N-(4,6–dimethyl-2–pyrindyl) benzamides. J Med Chem 28: 555–559, 1985

    PubMed  Google Scholar 

  22. Sampaio ER, Sarno EN, Galilly Z, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Med Chem 173: 699–703, 1991

    Google Scholar 

  23. Nishimura K, Hashimoto Y, Iwasaki S: Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide. Biochem Biophys Res Commun 199(2): 455–460, 1994

    PubMed  Google Scholar 

  24. Rankin PW, Jacobson EI, Benjamin RC, Moss J, Jacobson M: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264 (8): 4312–4317, 1989

    Google Scholar 

  25. Hirst DG, Joiner B, Hirst VK: Blood flow modification by nicotinamide and metoclopramide in mouse tumors growing in different sites. Br J Can 67: 1–6, 1993

    Google Scholar 

  26. Pellat-Deceurtynick C, Wietzerbin J, Drapier J-C: Nicotinamide inhibits nitric oxide synthase mRNA induction in acitvated macrophages. Biochem J 297: 53–58, 1994

    PubMed  Google Scholar 

  27. Wu H, Lozano G: NF-kB activation of p53. J Biol Chem 269: 20067–20074, 1994

    PubMed  Google Scholar 

  28. Graeber TG, Osamanian C, Jacks T, Houseman DE, Giaccia AJ: Hypoxia mediated selection of cells with diminished apoptoic potential in solid tumours. Nature 379: 88–91, 1996

    Article  PubMed  Google Scholar 

  29. Keiser A, Weich HA, Brandner G, Marme D, Kolch W: Mt p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963–969, 1994

    PubMed  Google Scholar 

  30. Poirier GG, Moreau P (eds): ADP-ribosylation reactions. Springer-Verlag, New York, pp. 1–410, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pero, R.W., Axelsson, B., Siemann, D. et al. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem 193, 119–125 (1999). https://doi.org/10.1023/A:1006932714982

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006932714982

Navigation